Filter zurücksetzen
Stichworte
Körperliche Untersuchung ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

789 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 27.09.16 - 1 Formular, 16 Itemgruppen, 104 Datenelemente, 1 Sprache
Itemgruppen: Medical and Surgical History, Significant Medical and Surgical History, NSCLC Diagnosis, NSCLC-related Surgery, Tobacco/Nicotine History at Randomization, Prior Adjuvant Chemotherapy, Prior Adjuvant Chemotherapy for NSCLC, Optional Research Blood Sample, Radiology, Vital Assessment, Physical Examination, Pregnancy Test, Hematology, Biochemistry/Proteomics, Study Drug Dispensed, Investigator's Signature
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Baseline Assessments

On-Treatment Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - On-Treatment Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 27.09.16 - 1 Formular, 10 Itemgruppen, 40 Datenelemente, 1 Sprache
Itemgruppen: Header, Vital Assessment, Physical Examination, Pregnancy Test, Hematology, Biochemistry/Proteomics, Cigarette Smoking Status, Tobacco/Nicotine Use Status, Radiology, Study Drug Dispensed
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: On-Treatment Assessments

Unscheduled Visit, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Unscheduled Visit, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 27.09.16 - 1 Formular, 11 Itemgruppen, 42 Datenelemente, 1 Sprache
Itemgruppen: Header, Vital Assessment, Physical Examination, Pregnancy Test, Hematology, Biochemistry/Proteomics, Cigarette Smoking Status, Tobacco/Nicotine Use Status, Radiology, Study Drug Dispensed Applicable, Study Drug Dispensed
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Unscheduled Visit

Post-Treatment Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Post-Treatment Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 27.09.16 - 1 Formular, 7 Itemgruppen, 18 Datenelemente, 1 Sprache
Itemgruppen: Vital Assessment, Physical Examination, Pregnancy Test, Biochemistry/Proteomics, Off Treatment Reason, Death, Investigator Signature
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Post-Treatment Assessments

Open-label Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Open-label Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 27.09.16 - 1 Formular, 8 Itemgruppen, 27 Datenelemente, 1 Sprache
Itemgruppen: Vital Assessment, Physical Examination, Pregnancy Test, Hematology, Biochemistry/Proteomics, Cigarette Smoking Status, Tobacco/Nicotine Use Status, Open-label Tarceva Dispensed
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Open-label Baseline Assessments

REFLECT-1 Visit 9 NCT00428090

- 25.09.16 - 1 Formular, 15 Itemgruppen, 27 Datenelemente, 1 Sprache
Itemgruppen: Patient Information, Central Laboratory Instructions, Investigator Instructions, Vital signs, Neurologic Examination, Central Laboratory, Pregnancy Test, 12-Lead ECG, Concomitant Medication, Adverse Event, Physical Examination, Pedal Oedema, Rating Scale Instrucitions, Investigational Product Compliance, End of Visit Reminder
NCT00428090 / GSK-AVA105640 A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)

REFLECT-1 Visit 3 NCT00428090

- 25.09.16 - 1 Formular, 12 Itemgruppen, 24 Datenelemente, 1 Sprache
Itemgruppen: Patient Information, Investigator Instructions, Subject Continuation, Vital signs, Central Laboratory, Concomitant medication, Adverse Event, Physical Examination, Pedal Oedema, Investigational Product, Compliance, End of Visit Reminder
NCT00428090 / GSK-AVA105640 A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)

REFLECT-1 Visit 2 NCT00428090

- 25.09.16 - 1 Formular, 10 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Patient Information, Investigator Instructions, Subject Continuation, Vital signs, Central Laboratory, Concomitant medication, Adverse Event, Physical Examination, Pedal Oedema, End of Visit Reminder
NCT00428090 / GSK-AVA105640 A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)

REFLECT-1 Visit 5 NCT00428090

- 25.09.16 - 1 Formular, 12 Itemgruppen, 24 Datenelemente, 1 Sprache
Itemgruppen: Patient Information, Investigator Instructions, Subject Continuation, Vital signs, Central Laboratory, Concomitant medication, Adverse Event, Physical Examination, Pedal Oedema, Investigational Product, Compliance, End of Visit Reminder
NCT00428090 / GSK-AVA105640 A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)

REFLECT-1 Visit 4 NCT00428090

- 25.09.16 - 1 Formular, 12 Itemgruppen, 24 Datenelemente, 1 Sprache
Itemgruppen: Patient Information, Investigator Instructions, Subject Continuation, Vital signs, Central Laboratory, Concomitant medication, Adverse Event, Physical Examination, Pedal Oedema, Investigational Product, Compliance, End of Visit Reminder
NCT00428090 / GSK-AVA105640 A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)

REFLECT-1 Visit 7 NCT00428090

- 25.09.16 - 1 Formular, 12 Itemgruppen, 24 Datenelemente, 1 Sprache
Itemgruppen: Patient Information, Investigator Instructions, Subject Continuation, Vital signs, Central Laboratory, Concomitant medication, Adverse Event, Physical Examination, Pedal Oedema, Investigational Product, Compliance, End of Visit Reminder
NCT00428090 / GSK-AVA105640 A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)

REFLECT-1 Visit 8 NCT00428090

- 25.09.16 - 1 Formular, 12 Itemgruppen, 24 Datenelemente, 1 Sprache
Itemgruppen: Patient Information, Investigator Instructions, Subject Continuation, Vital signs, Central Laboratory, Concomitant medication, Adverse Event, Physical Examination, Pedal Oedema, Investigational Product, Compliance, End of Visit Reminder
NCT00428090 / GSK-AVA105640 A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video